BIIB142 / Biogen, C4 Therap - LARVOL DELTA

IRAK4 degrader (BIIB142) for autoimmune disease, including lupus, initiated Phase 1 study in healthy volunteers (Biogen Press Release) - "Added a preclinical C5aR1 antagonist through a licensing agreement with Vanqua Bio, adding a proven immune mechanism with the potential to address a broad range of inflammatory disorders"

Trial status • Immunology

A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old (clinicaltrials.gov) - P1 | N=78 | Recruiting | Sponsor: Biogen | Not yet recruiting ➔ Recruiting

Enrollment open

C4 Therapeutics, Inc…announced that its partner Biogen has had its investigational new drug (IND) application for BIIB142 accepted by the U.S. Food and Drug Administration (FDA). (The Manila Times)

IND • Immunology